70 related articles for article (PubMed ID: 19921275)
1. Identification of cultivation condition to produce correctly folded form of a malaria vaccine based on Plasmodium falciparum merozoite surface protein-1 in Escherichia coli.
Mazumdar S; Sachdeva S; Chauhan VS; Yazdani SS
Bioprocess Biosyst Eng; 2010 Aug; 33(6):719-30. PubMed ID: 19921275
[TBL] [Abstract][Full Text] [Related]
2. High-level production and purification of P30P2MSP1(19), an important vaccine antigen for malaria, expressed in the methylotropic yeast Pichia pastoris.
Brady CP; Shimp RL; Miles AP; Whitmore M; Stowers AW
Protein Expr Purif; 2001 Dec; 23(3):468-75. PubMed ID: 11722185
[TBL] [Abstract][Full Text] [Related]
3. IgG subclass antibodies to three variants of Plasmodium falciparum merozoite surface protein-1 (PfMSP-1(19)) in an area with unstable malaria transmission in Iran.
Mehrizi AA; Asgharpour S; Salmanian AH; Djadid ND; Zakeri S
Acta Trop; 2011 Aug; 119(2-3):84-90. PubMed ID: 21609709
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village.
Perraut R; Marrama L; Diouf B; Sokhna C; Tall A; Nabeth P; Trape JF; Longacre S; Mercereau-Puijalon O
J Infect Dis; 2005 Jan; 191(2):264-71. PubMed ID: 15609237
[TBL] [Abstract][Full Text] [Related]
5. Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.
Gupta PK; Mukherjee P; Dhawan S; Pandey AK; Mazumdar S; Gaur D; Jain SK; Chauhan VS
Clin Vaccine Immunol; 2014 Jun; 21(6):886-97. PubMed ID: 24789797
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
Sachdeva S; Mohmmed A; Dasaradhi PV; Crabb BS; Katyal A; Malhotra P; Chauhan VS
Vaccine; 2006 Mar; 24(12):2007-16. PubMed ID: 16377036
[TBL] [Abstract][Full Text] [Related]
7. Proteome analysis reveals a large merozoite surface protein-1 associated complex on the Plasmodium falciparum merozoite surface.
Ranjan R; Chugh M; Kumar S; Singh S; Kanodia S; Hossain MJ; Korde R; Grover A; Dhawan S; Chauhan VS; Reddy VS; Mohmmed A; Malhotra P
J Proteome Res; 2011 Feb; 10(2):680-91. PubMed ID: 21175202
[TBL] [Abstract][Full Text] [Related]
8. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
[TBL] [Abstract][Full Text] [Related]
9. Plasmodium falciparum: sequence analysis of the gene encoding the C-terminus region of the merozoite surface protein-1, a potential malaria vaccine antigen, in Iranian clinical isolates.
Mehrizi AA; Zakeri S; Salmanian AH; Sanati MH; Djadid ND
Exp Parasitol; 2008 Mar; 118(3):378-85. PubMed ID: 18053992
[TBL] [Abstract][Full Text] [Related]
10. Assistance of maltose binding protein to the in vivo folding of the disulfide-rich C-terminal fragment from Plasmodium falciparum merozoite surface protein 1 expressed in Escherichia coli.
Planson AG; Guijarro JI; Goldberg ME; Chaffotte AF
Biochemistry; 2003 Nov; 42(45):13202-11. PubMed ID: 14609331
[TBL] [Abstract][Full Text] [Related]
11. Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate.
Bonnet S; Pêtres S; Holm I; Fontaine T; Rosario S; Roth C; Longacre S
Vaccine; 2006 Aug; 24(33-34):5997-6008. PubMed ID: 16814434
[TBL] [Abstract][Full Text] [Related]
12. Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrained.
Daubenberger CA; Nickel B; Ciatto C; Grütter MG; Pöltl-Frank F; Rossi L; Siegler U; Robinson J; Kashala O; Patarroyo ME; Pluschke G
Eur J Immunol; 2002 Dec; 32(12):3667-77. PubMed ID: 12516559
[TBL] [Abstract][Full Text] [Related]
13. Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42 kDa merozoite surface protein 1 (MSP1(42)) in the absence of an affinity tag.
Shimp RL; Martin LB; Zhang Y; Henderson BS; Duggan P; MacDonald NJ; Lebowitz J; Saul A; Narum DL
Protein Expr Purif; 2006 Nov; 50(1):58-67. PubMed ID: 16884920
[TBL] [Abstract][Full Text] [Related]
14. Vaccine candidate MSP-1 from Plasmodium falciparum: a redesigned 4917 bp polynucleotide enables synthesis and isolation of full-length protein from Escherichia coli and mammalian cells.
Pan W; Ravot E; Tolle R; Frank R; Mosbach R; Türbachova I; Bujard H
Nucleic Acids Res; 1999 Feb; 27(4):1094-103. PubMed ID: 9927744
[TBL] [Abstract][Full Text] [Related]
15. Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species.
O'Donnell RA; Saul A; Cowman AF; Crabb BS
Nat Med; 2000 Jan; 6(1):91-5. PubMed ID: 10613831
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and immunological characterization of E. coli expressed 42 kDa fragment of Plasmodium vivax and P. cynomolgi bastianelli merozoite surface protein-1.
Kaushal DC; Kaushal NA; Narula A; Kumar N; Puri SK; Dutta S; Lanar DE
Indian J Biochem Biophys; 2007 Dec; 44(6):429-36. PubMed ID: 18320841
[TBL] [Abstract][Full Text] [Related]
17. Enhanced expression of a recombinant malaria candidate vaccine in Escherichia coli by codon optimization.
Zhou Z; Schnake P; Xiao L; Lal AA
Protein Expr Purif; 2004 Mar; 34(1):87-94. PubMed ID: 14766303
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.
Stowers AW; Cioce V; Shimp RL; Lawson M; Hui G; Muratova O; Kaslow DC; Robinson R; Long CA; Miller LH
Infect Immun; 2001 Mar; 69(3):1536-46. PubMed ID: 11179324
[TBL] [Abstract][Full Text] [Related]
19. Protein-protein interaction studies reveal the
Paul G; Deshmukh A; Kumar Chourasia B; Kalamuddin M; Panda A; Kumar Singh S; Gupta PK; Mohmmed A; Chauhan VS; Theisen M; Malhotra P
Biochem J; 2018 Mar; 475(6):1197-1209. PubMed ID: 29511044
[No Abstract] [Full Text] [Related]
20. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.
Yuen D; Leung WH; Cheung R; Hashimoto C; Ng SF; Ho W; Hui G
Vaccine; 2007 Jan; 25(3):490-9. PubMed ID: 16949181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
